about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Al­ler­gy Ther­a­peu­tic­s' im­munother­a­py prospect tar­nished af­ter birch vac­cine flops in PhI­II

7 years ago
R&D

On­col­o­gy dom­i­nates a 'Cam­bri­an ex­plo­sion' in Chi­na's drug pipeline as McK­in­sey gu­ru bets on a burst of in­no­va­tion

7 years ago
China

As­traZeneca vet Jen­nifer But­ler takes charge of In­nate Phar­ma's US biz; C4 raids NI­BR

7 years ago
Peer Review

Roche clinch­es EU ap­proval for MabThera in rare au­toim­mune in­di­ca­tion — will it boost dwin­dling sales amid ...

7 years ago
Pharma

Biotech C4 raids NI­BR for new CMO; EU reg­u­la­tors green­light Hem­li­bra ex­pand­ed la­bel

7 years ago
News Briefing

Deer­field takes trans­la­tion­al part­ner­ship mod­el to Har­vard with $100M deal

7 years ago
Startups
R&D

Cam­bridge's TriNetX rais­es $40M for clin­i­cal an­a­lyt­ics plat­form; Nov­aBay chops its sales force, ap­points new chief

7 years ago
News Briefing

Em­ma Walm­s­ley earns £1M pay rise in her first full year at GSK's helm — but £5.9M pack­age still trails oth­er Big ...

7 years ago
People

Backed by Or­biMed, Lil­ly and now Ad­van­tech, Chi­na's In­ven­tis­Bio loads up $70M to pro­pel can­cer, meta­bol­ic pipeline

7 years ago
Financing
China

FDA of­fers quick thumbs up to ex­pand Dupix­en­t's atopic der­mati­tis la­bel as Re­gen­eron/Sanofi plot block­buster moves

7 years ago
Pharma

Is sec­ond time the charm for ozan­i­mod? Cel­gene starts to find out with EMA fil­ing

7 years ago
Pharma

Roche claims a first in breast can­cer as Tecen­triq/Abrax­ane com­bo nabs quick ap­proval in front­line use

7 years ago
Pharma

From Agios to De­ci­phera, Steve Ho­ert­er plots an­oth­er on­col­o­gy launch; Roche ex­ec Chris­tiane Hamachar moves to In­dia ...

7 years ago
Peer Review

'We can't': Jeff Lei­den stands his ground as MPs grill Ver­tex on pric­ing dis­agree­ment with NHS

7 years ago
Pharma

FDA pins an­oth­er 'break­through' badge on Ab­b­Vie's vene­to­clax; Ex­press Scripts bats back at drug­mak­ers on pric­ing

7 years ago
News Briefing

CAR-T shows promise for lu­pus in mouse study — will it in­spire hope in a be­lea­guered field?

7 years ago
Discovery

Fol­low­ing key late-stage ad­vances, BeiGene puts down $10M to get some dis­cov­ery projects rolling at Am­brx

7 years ago
R&D
Pharma

Cit­ing lin­ger­ing con­cerns, FDA stops Evoke at the 10-yard line a month be­fore PDU­FA date

7 years ago
Pharma

Build­ing on mo­men­tum from pos­i­tive di­a­betes da­ta, Zaf­gen scoops Bio­gen alum Priya Sing­hal as head of R&D

7 years ago
People

Af­ter neb­u­liz­er flop, Verona touts in­ter­im PhII re­sults on an­oth­er ver­sion of its lead COPD drug

7 years ago
R&D

Re­Vi­ral taps Seth Het­her­ing­ton to guide up­com­ing PhI­Ia; In­cyte, Aquinox ex­ecs move to AI shop No­table Labs

7 years ago
Peer Review

Abpro bags $60M in near-term R&D cash in tie-up with Chi­na's NJCT­TQ, with eyes on bis­pe­cif­ic T cell en­gagers

7 years ago
China
Pharma

Ea­ger to think big­ger than Chi­na, As­cle­tis woos top Mer­ck ex­ec to run R&D

7 years ago
People

An­oth­er PhI­II RSV fail­ure thumps be­lea­guered No­vavax, but ex­ecs claim there's a way for­ward

7 years ago
R&D
First page Previous page 102103104105106107108 Next page Last page
A service from the Financial Times